Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Litton JK, et al. Among authors: ettl j. Ann Oncol. 2020 Nov;31(11):1526-1535. doi: 10.1016/j.annonc.2020.08.2098. Epub 2020 Aug 20. Ann Oncol. 2020. PMID: 32828825 Free PMC article. Clinical Trial.
Update Breast Cancer 2023 Part 3 - Expert Opinions of Early Stage Breast Cancer Therapies.
Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, Fasching PA, Janni W, Witzel I, Thomssen C, Beierlein M, Belleville E, Untch M, Thill M, Tesch H, Ditsch N, Lux MP, Aktas B, Banys-Paluchowski M, Kolberg-Liedtke C, Wöckel A, Harbeck N, Stickeler E, Bartsch R, Schneeweiss A, Ettl J, Krug D, Taran FA, Lüftner D, Würstlein R. Kolberg HC, et al. Among authors: ettl j. Geburtshilfe Frauenheilkd. 2023 Sep 12;83(9):1117-1126. doi: 10.1055/a-2143-8125. eCollection 2023 Sep. Geburtshilfe Frauenheilkd. 2023. PMID: 37706055 Free PMC article.
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ. Finn RS, et al. Among authors: ettl j. Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16. Lancet Oncol. 2015. PMID: 25524798 Clinical Trial.
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, Diéras V, Moulder S, Lipatov O, Colleoni M, Cristofanilli M, Lu DR, Mori A, Giorgetti C, Iyer S, Bartlett CH, Gelmon KA. Turner NC, et al. Among authors: ettl j. Ann Oncol. 2018 Mar 1;29(3):669-680. doi: 10.1093/annonc/mdx797. Ann Oncol. 2018. PMID: 29342248 Free PMC article. Clinical Trial.
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
Rugo HS, Diéras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CHUANG, Iyer S, Johnston S, Ettl J, Harbeck N. Rugo HS, et al. Among authors: ettl j. Ann Oncol. 2018 Apr 1;29(4):888-894. doi: 10.1093/annonc/mdy012. Ann Oncol. 2018. PMID: 29360932 Free PMC article. Clinical Trial.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Litton JK, et al. Among authors: ettl j. N Engl J Med. 2018 Aug 23;379(8):753-763. doi: 10.1056/NEJMoa1802905. Epub 2018 Aug 15. N Engl J Med. 2018. PMID: 30110579 Free PMC article. Clinical Trial.
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. Ettl J, et al. Ann Oncol. 2018 Sep 1;29(9):1939-1947. doi: 10.1093/annonc/mdy257. Ann Oncol. 2018. PMID: 30124753 Free article. Clinical Trial.
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.
Hurvitz SA, Quek RGW, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke E, Mina LA, Balmaña J, Fasching PA, Bhattacharyya H, Hannah AL, Robson ME, Wardley AM. Hurvitz SA, et al. Among authors: ettl j. Eur J Cancer. 2018 Nov;104:160-168. doi: 10.1016/j.ejca.2018.09.003. Epub 2018 Oct 22. Eur J Cancer. 2018. PMID: 30359909 Clinical Trial.
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME; ABRAZO Study Group. Turner NC, et al. Among authors: ettl j. Clin Cancer Res. 2019 May 1;25(9):2717-2724. doi: 10.1158/1078-0432.CCR-18-1891. Epub 2018 Dec 18. Clin Cancer Res. 2019. PMID: 30563931 Clinical Trial.
111 results